聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎疗效观察

摘要

Objective To investigate the efficacy of long-acting interferon (peginterferon alfa-2b, PEG-IFNα-2b) plus ribavirin for treating chronic hepatitis C(CHC) in comparison with that of conventional interferon alfa-2b (IFNα-2b) plus ribavirin. Methods A total of 96 consecutive, treatment-naive, HCV RNA-positive patients with chronic hepatitis were randomly assigned to once weekly PEG-IFNα-2b(Observational group, n=48) or every other day IFNα-2b(Control group, n=48) plus ribavirin for 48 weeks. The rates of early-, end of treatment-, and sustained- virological response (VR) to-gether with the safety and adverse-event profiles between the two groups were compared. Results More patients in obser-vational group than control group achieved an early VR (χ2=6.27,P<0.05), an end of treatment VR (χ2=4.17,P<0.05) and a sustained VR(χ2=4.44,P<0.05). The safety profile was similar between the two groups(χ2=0.12,P>0.05). Conclu-sions PEG-IFNα-2b plus ribavirin is more effective than IFNα-2b plus ribavirin for treating CHC, but its sustained VR rate needs further improvement.%目的：以普通干扰素（IFN）α-2b联合利巴韦林为对照，观察聚乙二醇干扰素（PEG-IFN）α-2b联合利巴韦林治疗慢性丙型肝炎（CHC）的临床疗效。方法成人CHC患者96例随机分为两组，每组48例，观察组给予PEG-IFNα-2b，对照组给予IFNα-2b，均联合利巴韦林口服，疗程48周。观察两组早期病毒学应答（EVR）、治疗结束时病毒学应答（ETVR）、持久病毒学应答（SVR）和安全性等方面的差异。结果观察组EVR率、ETVR 率、SVR率均高于对照组（χ2分别=6.27、4.17、4.44，P均＜0.05）。两组不良反应发生率差异无统计学意义（χ2=0.12，P＞0.05）。结论PEG-IFNα-2b联合利巴韦林治疗CHC疗效优于普通干扰素联合利巴韦林，但SVR率需要进一步提高。